Tekamlo

Tekamlo is a brand name of aliskiren/amlodipine, approved by the FDA in the following formulation(s):

TEKAMLO (aliskiren hemifumarate; amlodipine besylate - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: August 26, 2010
  
  Strength(s): EQ 150MG BASE;EQ 10MG BASE, EQ 150MG BASE;EQ 5MG BASE, EQ 300MG BASE;EQ 10MG BASE ^[RLD], EQ 300MG BASE;EQ 5MG BASE
  

Has a generic version of Tekamlo been approved?

No. There is currently no therapeutically equivalent version of Tekamlo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tekamlo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Tekamlo.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 5, 2012 - NEW CHEMICAL ENTITY
  
  
  • August 26, 2013 - NEW COMBINATION
  
  

See also...

• Tekamlo Consumer Information (Drugs.com)
• Tekamlo Consumer Information (Wolters Kluwer)
• Tekamlo Consumer Information (Cerner Multum)
• Tekamlo Advanced Consumer Information (Micromedex)
• Aliskiren/Amlodipine Consumer Information (Wolters Kluwer)
• Aliskiren and amlodipine Consumer Information (Cerner Multum)
• Aliskiren and amlodipine Advanced Consumer Information (Micromedex)